Hims & Hers Health Inc. (NYSE: HIMS) closed the day trading at $6.85 up 2.09% from the previous closing price of $6.71. In other words, the price has increased by $+0.14 from its previous closing price. On the day, 1566294 shares were traded.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Ratios:
For a better understanding of HIMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 121.03. For the most recent quarter (mrq), Quick Ratio is recorded 3.20 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on July 28, 2023, initiated with a Outperform rating and assigned the stock a target price of $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 21 when Okupe Oluyemi sold 6,698 shares for $6.92 per share. The transaction valued at 46,319 led to the insider holds 125,016 shares of the business.
O’Keefe Lynne Chou sold 45,748 shares of HIMS for $327,098 on Aug 14. The Director now owns 0 shares after completing the transaction at $7.15 per share. On Aug 08, another insider, Dudum Andrew, who serves as the Chief Executive Officer of the company, sold 6,900 shares for $9.04 each. As a result, the insider received 62,382 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 1.45B and an Enterprise Value of 1.26B. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.99 while its Price-to-Book (P/B) ratio in mrq is 4.45. Its current Enterprise Value per Revenue stands at 1.77 whereas that against EBITDA is -28.79.
Stock Price History:
Over the past 52 weeks, HIMS has reached a high of $12.34, while it has fallen to a 52-week low of $4.01. The 50-Day Moving Average of the stock is 7.99, while the 200-Day Moving Average is calculated to be 8.56.
Shares Statistics:
Over the past 3-months, HIMS traded about 3.05M shares per day on average, while over the past 10 days, HIMS traded about 1.91M shares per day. A total of 208.42M shares are outstanding, with a floating share count of 176.49M. Insiders hold about 0.80% of the company’s shares, while institutions hold 58.20% stake in the company. Shares short for HIMS as of Aug 14, 2023 were 17.68M with a Short Ratio of 17.68M, compared to 24.49M on Jul 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.38% and a Short% of Float of 11.30%.
Earnings Estimates
Current recommendations for the stock of the company come from 8 analysts. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.04, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.02 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.12 and -$0.18 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.06, with 8 analysts recommending between $0 and -$0.18.
Revenue Estimates
9 analysts predict $220.08M in revenue for the current quarter. It ranges from a high estimate of $222.3M to a low estimate of $218.2M. As of the current estimate, Hims & Hers Health Inc.’s year-ago sales were $130.34M, an estimated increase of 68.90% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $227.34M, an increase of 36.00% less than the figure of $68.90% in the same quarter last year. There is a high estimate of $231.38M for the next quarter, whereas the lowest estimate is $220.6M.
A total of 10 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $851.65M, while the lowest revenue estimate was $837.5M, resulting in an average revenue estimate of $846.37M. In the same quarter a year ago, actual revenue was $526.92M, up 60.60% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $1.05B in the next fiscal year. The high estimate is $1.11B and the low estimate is $968.3M. The average revenue growth estimate for next year is up 23.90% from the average revenue estimate for this year.